In PD model mice, a 3-week EA in GV20 and GV14 ameliorated motor impairments and dopaminergic neuron loss and increased the levels of BDNF and GDNF in the substantia nigra and striatum (Pak et al., 2019). The gene discussed is GDNF; the disease is Parkinson disease.